In 2007, the NCCN update has added the regimen CapeOx, a combination of capecitabine (Xeloda, Roche) and oxaliplatin (Eloxatin, Sanofi-Aventis), as an alternative to FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) for the treatment of advanced or metastatic colon cancer. The majority of safety and efficacy data for CapeOx have come from Europe, where administration of capecitabine at a starting dose of 1000 mg/m2 twice daily for 14 days, to be repeated every 21 days, is standard. There is some evidence that North American patients may experience greater toxicity with capecitabine, and other fluoropyrimidines, than the Europeans and may require a lower dose. However, because the efficacy of the drug at lower doses has not been evaluated in large, randomized trials, NCCN still recommends a starting dose of 1000 mg/m2 with close monitoring in the first cycle for toxicity and possible dosage adjustments.
Anna Pessino, Alberto Sobrero Optimal treatment of metastatic colorectal cancer Expert Review of Anticancer Therapy 2006 6:5, 801-812
Cercek A, Saltz LB. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S47-51.